Skip to main content
. 2019 Sep;11(9):3712–3720. doi: 10.21037/jtd.2019.09.36

Figure 2.

Figure 2

Comparison of intrapleural PFS (iPFS) and PFS in EGFR 19 deletion and 21L858R-mutated patients (n=59) who underwent pleural effusion drainage or continued EGFR-TKI when disease progression until disease progression again and a modified therapeutic regimen. (A) Comparison of iPFS between exon 19 and 21L858R mutations patients with MPEs were 12.0 versus 10.7 months, respectively (P=0.096); (B) the PFS between exon 19 and 21L858R mutations was 11.2 versus 6.5 months, respectively (P=0.010). PFS, progression-free survival; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; MPE, malignant pleural effusion.